2014

CO2 Solutions Announces Extension of its Agreement with Procede Group B.V.

Leading gas absorption technology company confirms exclusivity with CO2 Solutions for enzyme-based carbon capture

TSXV: CST 
Outstanding shares: 79,187,836 

QUEBEC CITY, QC, Dec. 17, 2012 /PRNewswire/ - CO2 Solutions Inc. (TSX-V:CST), an innovator in the field of enzyme-enabled carbon capture technology, today announced it has extended its Consulting and Technology Transfer Agreement with Procede Group B.V. ("Procede") for the continued development of CO2 Solutions' proprietary enzyme-based carbon capture technology.

Under the terms of the extended Agreement, Procede will remain exclusive to CO2 Solutions for all work in the field of enzyme-enhanced carbon capture, including the execution of the Company's recently announced project in the Alberta oil sands. CO2 Solutions will also continue to benefit from a license to all of Procede's intellectual property pertaining to carbon capture using carbonic anhydrase or any variants.

"We are excited to continue our relationship with Procede to support the technology development, scale up and commercialization of our carbon capture technology," said Glenn Kelly, President and CEO of CO2 Solutions. "Procede is well-known throughout the industry for its advisory work in gas scrubbing. Jointly we can leverage each other's expertise and industry contacts to help advance CO2 Solution's enzymatic carbon capture technology in North America and in Europe."

"Procede is pleased to continue this exclusive arrangement with CO2 Solutions, the leading company in the field of enzyme-enhanced carbon capture," said Dr. Geert Versteeg, Procede's co-founder. "We look forward to working closely with CO2 Solutions to help commercialize its technology, which I believe can be seen as a promising breakthrough technology for low-cost carbon capture from large industrial sources of carbon dioxide."

As partial consideration for previously supplied business development services provided by the two principals of Procede, each of their holding companies will receive 250,000 common shares of CO2 Solutions Inc. at a value of $0.20 per share. These shares will be subject to a four (4) month and one (1) day statutory hold period from the date of issuance.

The Agreement also provides for the continued technology transfer of certain of Procede's proprietary testing processes and methods to CO2 Solutions' facility in Quebec. Any new intellectual property developed under the Agreement by Procede and any associated rights will be the sole property of CO2 Solutions.

Procede will apply its expertise in gas absorption processes to continue to assist CO2 Solutions in the commercialization of its patented enzyme-based technology for carbon dioxide capture, including lab testing, process modelling and simulation, process development and design.  Procede will also be a partner with CO2 Solutions in the execution of its recently announced project in the Alberta oil sands to optimize CO2 Solutions' technology for the efficient capture of CO2 emissions from oil sands production - the single fastest growing source of carbon emissions in Canada.

Based in The Netherlands, Procede Group is a developer of custom processes requiring advanced chemical-engineering knowledge. A spin-off of Twente University of Technology, Procede employs a research, development and design staff of about 25 engineers and other scientific personnel and has performed work for numerous organizations in the oil and gas industry including Shell, Exxon-Mobil, Alstom, and Sulzer and has collaborated with CO2 Solutions on major projects with Alcoa and a global leader in energy infrastructure.

The technical effort under the Agreement will be supervised in part by Dr. Versteeg, in addition to his ongoing role as a member of CO2 Solution's Scientific Advisory Board. As Director and Co-Founder of Procede, Dr. Versteeg brings more than 30 years of professional experience in applied scientific research, including significant expertise in CO2 capture processes which the Company believes will be an important asset in its efforts to scale up and optimize its enzymatic carbon capture technology for commercial application.

About CO2 Solutions Inc.

CO2 Solutions is an innovator in the field of enzyme-enabled carbon capture and has been actively working to develop and commercialize the technology for stationary sources of carbon pollution.  CO2 Solutions' technology lowers the cost barrier to Carbon Capture, Sequestration and Utilization (CCSU), positioning it as a viable CO2 mitigation tool, as well as enabling industry to derive profitable new products from these emissions.  CO2 Solutions has built an extensive patent portfolio covering the use of carbonic anhydrase, or analogues thereof, for the efficient post‐combustion capture of carbon dioxide with low‐energy aqueous solvents.  Further information can be found at www.co2solutions.com.

CO2 Solutions Forward-looking Statements

Certain statements in this news release may be forward-looking. These statements relate to future events or CO2 Solutions' future economic performance and reflect the current assumptions and expectations of management. Certain unknown factors may affect the events, economic performance and results of operations described herein. CO2 Solutions undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE CO2 SOLUTIONS INC.



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.